Upcoming event

Tags

Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO21, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

European Urology, Volume 75, Issue 3, March 2019, Pages 368-373

The European Prostate Cancer Centres of Excellence: A novel proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting

European Urology, February 2019

Widespread and functional RNA circularization in localized prostate cancer

Cell, Volume 176, Issue 4, February 2019, Pages 831-843

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The LANCET Oncology, February 2019

Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population-based study

Cancer., February 2019

Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study

The Lancet Oncology, January 2019

Association Between Preoperative Magnetic Resonance Imaging–based Urethral Parameters and Continence Recovery Following Robot-assisted Radical Prostatectomy

European Urology Focus, January 2019

Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)

Are we improving functional outcomes of prostate cancer patients treated with robot-assisted radical prostatectomy? A 10-year analysis in men treated at two high volume, tertiary referral centers

Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis

Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for treatment selection

Molecular phenotypes in DNA repair deficiency correlate with specific clinical outcomes subtypes and genetic background

PreviousNext